Detection of Efflux Pump Genes (adeA, adeB, adeC and abeM) in Acinetobacter baumannii Isolated from Hospitalize Patients, North-west of Iran

Goli Angoti¹, Mojgan Bandehpour², Hossein Goudarzi³*, Maryam Hajizadeh⁴, Maryam zarringingham moghaddam⁴, Amaneh Kouchaki⁵

¹Department of Microbiology, Shahid Beheshti University, M.C International Branch, Tehran, IR Iran
²Department of Biotechnology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
³Shahid Beheshti University. M.C. International Branch, Tehran, IR Iran
⁴Department of Microbiology, Imam Reza Hospital, Tabriz, IR Iran

*Corresponding author: Hossein Goudarzi, Shahid Beheshti University. M.C. International Branch, Tehran, IR Iran. Tel: +98 (21) 23872556. E-mail: hgod500@yahoo.com

Submitted: June 22, 2016; Revised: august 22, 2016; Accepted: September 10, 2016

Background: The importance of this research was to determine the prevalence of efflux pump genes among Acinetobacter baumannii isolates from hospitalized patients in Imam Reza hospital in Tabriz, Iran.

Materials and Methods: This descriptive study was conducted in the Imam Reza hospital, Tabriz, IR Iran during June 2013 to March 2014. Twenty-six strains were isolated from female patients (42.6%) and thirty-five from male patients (57.4%). Clinical specimens were cultured for isolation of the microbial agents of A. baumannii. The isolated bacteria were identified using biochemical tests. Disk diffusion susceptibility test was used to determine the antimicrobial susceptibility, and E-test methods were also used. The prevalence of efflux pump genes was detected by PCR and sequencing methods.

Results: The resistance of A. baumannii isolates against tested antibiotics was analyzed as follows: 51 (84%) to trimethoprim-sulfamethoxazole, 59 (98%) to cefazidime, 60 (99%) to ciprofloxacin, 29 (48%) to amikacin, 46 (77%) to gentamicin, 30 (50%) to tobramycin, 60 (99%) to imipenem, 60 (99%) to meropenem, 60 (99%) to ceftiraxone, 60 (99%) to cefepime, 60 (99%) to ofloxacin, 6 (11%) to colistin. By using E-test, 45 (73.3%) to imipenem, 57 (93.3%) to ciprofloxacin, 23 (38%) to amikacin were also analyzed. The prevalence of adeA, adeB, adeC, and abeM genes was 54 (88.5%), 61 (100%), 57 (93.9%), and 60 (98.3%), respectively.

Conclusion: The result of this study showed high incidence of AdeABC efflux pump in MDR A. baumannii isolates and the growing number of nosocomial infections associated with XDR A. baumannii complex, leading to difficulties in antibiotic therapy.

Keywords: A. baumannii, Efflux pumps, PCR

1. Background

Acinetobacter baumannii known as a high importance nosocomial microorganism isolated specially from intensive care units (ICUs), that causes severe infections. A. baumannii is usually multi drug resistant (MDR), showing resistance to the third generation cephalosporins, aminoglycosides, and fluoroquinolone (1, 2). Newly, A. baumannii isolates have proved to be extensively drug-resistant (XDR) which is determined as resistance to all antibacterial agents except tigecycline and colistin. The treatment of XDR A. baumannii infection physicians unable to treat well and limited management experience. Unfortunately, the extend use of tigecycline and colistin as salvage therapy has been associated with high incidence of AdeABC efflux pump in MDR A. baumannii complex, leading to difficulties in antibiotic therapy.

The most common mechanisms for resistance can be a) intrinsic, because of chromosomally encoded cephalosporinase production and low level of membrane impermeability, b) acquired, transferring of foreign genetic information or mutation in endogenous structural or regulatory genes. Efflux systems are extensively available in microorganisms and admit resistance to various compounds including antibiotics, by deporting of the drug. As an important clinical issue are mutational events in the regulators of efflux systems, which simply can admit multidrug resistance (MDR) to the host by over expression of the pump. The pumps of the resistance-nodulation-cell division (RND) superfamily are common in Gram-negative bacteria and have the broadest substrate ranges (4).

Up to now, overexpression of three RND systems, AdeABC (5), AdeFGH (6), and AdeJK (7), has been related with MDR in A. baumannii (8). The first pump explicated, AdeABC, admits resistance to aminoglycosides, tetracyclines, fluoroquinolones, chloramphenicol, and trimethoprim, and decreased susceptibility to tigecycline (9-11). AdeABC, initially, and AdeFGH play a main role in acquired resistance (8), while AdeJK is responsible for intrinsic resistance (7). Production of AdeABC is controlled by a two-component regulatory system, AdeRS (12).

The another efflux pump, AbeM, which be a part of the multidrug and toxic compound extrusion (MATE) family, has also been characterized in isolates of A. baumannii (13). Substrates for the abeM efflux pump include gentamicin, ciprofloxacin, erythromycin, and trimethoprim (13). The help of this system to antimicrobial resistance in clinical isolates is unknown.

2. Objectives

This study aims to determine the prevalence of adeA, adeB, adeC, and abeM genes among A. baumannii strains isolated from patients admitted to Imam Reza medical center, Tabriz, IR Iran.
3. Materials and Methods

This study was performed in the Imam Reza medical center laboratory in Tabriz in East Azerbaijan, northwest of IR Iran from June 2013 to march 2014.

3.1. Bacterial isolates

Sixty-one strains of A. baumannii were isolated from blood, wound, absceses, urine, sputum, respiratory tract, and fluid bodies of patients from Imam Reza medical center in Tabriz, IR Iran. The isolates were assigned by conventional biochemical methods (14) and confirmed for blaOXA-23 to the species.

3.2. Susceptibility testing

In this study, antibiotic susceptibility pattern was performed on Mueller-Hinton Agar (Merck, Germany) by Kirby Bauer's disk diffusion technique. This method was done according to CLSI recommendations 2012 (15). Antimicrobial agents tested were the antibiotic disks which were comprised of: imipenem (IPM)(10μg), meropenem (MER)(10μg), ceftazidime (CAZ)(30μg), cefotaxime (CTX)(30μg), amikacin (AN)(30μg), colistin(COL)(10μg), ciprofloxacin (CP)(5μg), celeplume (FEP)(30μg), trimethoprim-sulfamethoxazole (TS) (2.5μg), tobramycin (TOB)(30 μg), ceftiraxon (CRO)(30μg), and gentamicin (GM)(10μg) (Hi Media, India; padantehe, Iran). The results were interpreted based on inhibition zone. E. coli ATCC 25922 was used as the quality control strain for antimicrobial susceptibility test.

3.3. E-test

The MICs of imipenem, ciprofloxacin, and amikacin (AB Biodisk, Solna, Sweden) were determined using E-test method according CLSI 2012 (15).

3.4. Genomic DNA extraction

Genomic DNAs for PCR were prepared by boiling method briefly; the bacteria were cultured on nutrient agar. After one overnight, a colony was inoculated in 3 mL ofuria Bertoni broth. After that, it was inoculated at 37°C on incubator for 20-24 hr. After incubation, 1.5 mL of the culture medium was poured into microtubes and centrifuged for 5 min 14000 rpm. Then Supernatant was removed and 500 mL distilled water added to the pellet. The suspension was heated for 10 min at 95°C. The heated suspension was centrifuged again at 14000 rpm for 5 min. Supernatant containing DNA was extracted and used as template for PCR techniques.

3.5. PCR of adeA, adeB, adeC, and adeM genes

Efflux pump genes, adeA, adeB, adeC, and adeM, were detected by PCR with designed specific primers, which are presented in Table 1. The PCR assay was done in 20μL of reaction mixture containing: 1.5U Taq DNA polymerase (Fermentas), 0.5μL dNTPs (Fermentas), 5mM MgCl2, 2.5μL of 10X PCR buffer, 1 μL of the purified nucleic acid solutions, and a 1μM of each primer. The thermal profile involved 5 min at 95°C for initial denaturation step, 30 cycles of 30s at 95°C, primer annealing temperature was set up for adeA at 44°C for 30s, for adeB at 46°C for 30s, for adeC and adeM at 55°C for 30s. The extension was also set up at 72°C for 30s. The cycling was done according to a final extension step at 72°C for 5 min. PCR products were analyzed by 1% agarose gel and stained with ethidium bromide. Statistical analyses were calculated by using SPSS16 software. X2 statistical significance was defined as P-value <0.05.

3.6. Nucleotide Sequencing

PCR purification kit (Bioneer Co., Korea) was used to purify PCR products, and sequencing was performed by the Pioneer Company (Korea). The nucleotide sequences were analyzed with the Chromas 1.45 software and the BLAST program from the National Center for Biotechnology Information website (http://www.ncbi.nlm.nih.gov/BLAST). The nucleotide sequences of adeA, adeB, and adeC were submitted to the GenBank database and assigned accession numbers from AB982118.1 to AB982122, LC016875.1 to LC016884.1 and LC016625.1 to LC016633.1.

4. Results

In this study, sixty-one strains were isolated from Imam Reza medical center. Twenty-six strains were isolated from female patients (42.6%) and thirty-five from male patients (57.4%). Of the 61 isolates, 30 (49.3%) from tracheal tube were isolated, 7 (11.6%) from wound, 10 (16.7%) from blood, 4 (6.5%) from urine, 5 (8.4%) from sputum, and 5 (7.5%) from CSF, asites, and other cases. The age range of the patients was from 1 to 90 years. The isolates were obtained from patients in different age groups: 1–29 years (n = 7), 30–39 years (n = 6), 40–49 years (n = 8), 50–59 years (n = 14), 60–69 years (n = 12), and 70–79 years (n = 10), and four isolates were isolated from patients more than eighty years old. The resistance of A. baumannii isolates against tested antibiotics was analyzed as follows: trimethoprim-sulfamethoxazole 51 (84%), ceftazidime 59 (98%), ciprofloxacin 60 (99%), amikacin 29 (48%), gentamicin 46 (77%), tobramycin 30 (50%), imipenem 60 (99%), meropenem 60 (99%), ceftiraxon 60 (99%), cefepime 60 (99%), ofloxacin 60 (99%), colistin 6 (11%) (Table 2).

### Table 1. The targeted genes and related design primers used for amplification.

| Gene   | Primers                  | Product size |
|--------|--------------------------|--------------|
| adeA-R | 5'- CTGATAYTCTAAGGAGGTTG-3' | 408 bp       |
| adeB-R | 5'- GCTCCTCCTAATAGGATGA -3' | 340 bp       |
| adeC-R | 5'- GTAAACCTTGACGTACGACT -3' | 222 bp       |
| adeM-R | 5'- GCTGGTGCAATCATGATGGCA -3' | 283 bp       |

### Table 2. Antibiotic resistance of A.baumannii strains.

| Antibiotic           | Resistance |
|----------------------|------------|
| Cefuroxime           | 99         |
| Ceftazidime          | 99         |
| Ceftiraxone          | 99         |
| Imipenem             | 99         |
| Tobramycin           | 98         |
| Gentamicin           | 99         |
| Amikacin             | 99         |
| Tobramycin           | 99         |
| Ceftriaxon           | 98         |
| Ceftazidime          | 98         |
| Tobramycin           | 99         |
| Amikacin             | 99         |
| Tobramycin           | 99         |

The prevalence of adeA, adeB, adeC, and adeM genes among 61 A. baumannii isolates was 54 (88.5%), 61 (100%), 57 (93.9%), and 60 (98.3%), respectively (Figure1-5). blDoxA-51 was investigated and detected in all strains. Sequencing of PCR products revealed conserved regions for the restricted
sequence of adeA, adeB, adeC, and abeM genes, which was confirmed by BLAST in NCBI.

5. Discussion

Nosocomial outbreaks of MDR A. baumannii have been demonstrated in many studies (16, 17, 18). Many studies has been shown the outbreak of PDR A. baumannii. In this study A. baumannii was highly sensitive to colistin (89%) and moderately sensitive to amikacin (52%) and tobramycin (50%). Despite the high sensitivity of Acinetobacter to colistin, its use should be limited to life threatening conditions because of serious neurological and renal side effects (19, 20). Another point in the current study was concerned problem is related to their multidrug resistance which restricts the treatment procedure (14). Several studies have clearly indicated that the incidence of resistant A. baumannii strains is increasing worldwide (21). In general, susceptibility rates of A. baumannii isolates to third- and fourth-generation cephalosporins, carbapenems, fluoroquinolones, and trimethoprim/sulfamethoxazole (SXT) were very low.

In this study, the resistance to imipenem, ciprofloxacin, and amikacin by using E-test were 73.3, 93.3, and 38%, respectively, while resistance rates were reported by Boroumand et al. 53.4 and 24.6% to ciprofloxacin and imipenem, respectively (22). The gene adeB codes multidrug efflux pump for the transmembrane protein of AdeABC. All isolates in the current study were found to carry the adeB gene. As illustrated by Magnet et al., disruption of this gene leads to the loss of multidrug resistance (5). Because of its necessity for AdeABC function, we investigated the prevalence of
References

1. Sinha M, Srinivas H. Mechanism of resistance to ciprofloxacin-resistant Acinetobacter isolates from clinical sample. Ind J Med Microbiol. 2007; 25(2): 121-5.

2. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005; 41(6): 648-54.

3. Shidler RK, Clancy CJ, Gillis LM, Kwaak EI, Silveira FP, Masoli RC, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One. 2012; 7(12): e52349.

4. Li ZX, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs. 2009; 69(12): 1555–623.

5. Magniet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in amikacin resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother. 2001; 45(12): 3735-80.

6. Coyne S, Rosenfeld N, Lambert T, Courvalin P, Perichon B. Overexpression of resistance-nodulation-cell division pump AdeFGH admits multidrug resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2010; 54(11): 4389-93.

7. Damiet-Poile L, Magniet S, Bremont S, Lambert T, Courvalin P. AdeEJK, a resistance-nodulation-cell division pump effecting multiple antibiotics in resistance-NRC-1 is tolerant to amikacin. Antimicrob Agents Chemother. 2008; 52(2): 557-62.

8. Coyne S, Courvalin P, Perichon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother. 2011; 55(3): 947-53.

9. Pelig AX, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51(6): 2665-9.

10. Ruzin A, Immermann FW, Bradford PA. RT-PCR and statistical analyses of adeABC expression in clinical isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Microb Drug Resist. 2010; 16(2): 87 – 9.

11. Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother. 2007; 59(5): 1001-4.

12. Marchand I, Damiet-Poile L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii regulated by the AdeR/K two-component system. Antimicrob Agents Chemother. 2004; 48(9): 3208 – 3304.

13. Su XZ, Chen J, Mizutahina T, Kuroda T, Tsuchiya T, AbeM, an H+–coupled Acinetobacter baumannii multidrug efflux pump belonging to the MATE family of transporters. Antimicrob Agents Chemother. 2005; 49(10): 4362–4.

14. Shahcheraghif G, Abbasalipour M, Feizabadi MM, Ebrahimpour GH, Akbari N. “Isolation and genetic characterization of adeABC, adeFGH and adeABC multidrug efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii” in bacteriophage infection. Iran J Microbiol. 2011; 3(2): 68 – 74.

15. Clinical and Laboratory Standards Institute (CLSI). “Performance standards for antimicrobial susceptibility testing. Twentieth-second informational supplement”. Tech Rep. M100–22. Fort Wayne, Ind., USA. 2012.

16. del Mar Tomas M, Cartelle M, Pertega S, Recuerto A, Linares P, Canle D, et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect. 2005; 11(7): 540-6.

17. Villegas MV, Hartstein AL. Acinetobacter baumannii: a opportunistic pathogen in hospital settings. The acquisition of resistance and overexpression of efflux pumps provide a successful strategy to survive, adapt, and be selected in this environment. Hence, using standard assays for susceptibility test and MIC breakpoint could be achieved to accurately monitor the resistant strains. Furthermore, a new approach would be the effort to develop efflux inhibitors as a possible way for the proceeding of new agents to control antimicrobial resistance in nosocomial pathogens, developed hygiene procedures and optimal drug use are vital to limit the selection and reduction of such microorganisms.

Conflict of Interests

The authors declare they have no conflicts of interest.

Acknowledgments

The authors thank the effort of staff of microbiology department of Imam Reza medical center, Tabriz, IR Iran.

Authors’ Contribution

Goli Angoti and Maryam Hajizadeh collected the samples; Goli Angoti and Amane Kouchaki performed the experiments and wrote the manuscript; Maryam zarrinhalam moghadam analyzed data; Hossein Goudarzi and Mojgan Bandehpour were an instructor in the project and assessment to the analysis of the data.

Funding/Support

The work was financially supported by Shahid Beheshti University of Medical Sciences and Imam Reza medical center, Tabriz, IR Iran.

References

1. Sinha M, Srinivas H. Mechanism of resistance to ciprofloxacin-resistant Acinetobacter isolates from clinical sample. Ind J Med Microbiol. 2007; 25(2): 121-5.